Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Rating) have attained a consensus advice of “Buy” from the six exploration corporations that are presently masking the enterprise, Marketbeat.com stories. 6 equities research analysts have rated the inventory with a obtain suggestion. The typical 1-12 months target selling price amongst brokerages that have current their coverage on the stock in the very last yr is $19.17.
Numerous brokerages have a short while ago issued reviews on ABOS. HC Wainwright started protection on shares of Acumen Prescribed drugs in a exploration notice on Thursday, June 30th. They issued a “buy” ranking and a $15.00 cost aim on the inventory. Credit Suisse Team lowered their cost aim on shares of Acumen Prescribed drugs from $26.00 to $17.00 and set an “outperform” score on the inventory in a investigate be aware on Tuesday, March 29th. Lastly, BTIG Investigate started protection on shares of Acumen Prescribed drugs in a study notice on Friday. They issued a “buy” rating and a $15.00 price objective on the stock.
Institutional Buyers Weigh In On Acumen Prescribed drugs
Institutional buyers have not long ago bought and marketed shares of the business enterprise. California Condition Academics Retirement Procedure boosted its stake in Acumen Prescribed drugs by 114.9% during the initial quarter. California Condition Instructors Retirement Process now owns 12,162 shares of the company’s stock really worth $48,000 soon after buying an more 6,503 shares in the final quarter. Good Issue Associates LLC obtained a new stake in shares of Acumen Prescription drugs in the 1st quarter valued at $3,630,000. Deep Keep track of Capital LP boosted its stake in shares of Acumen Pharmaceuticals by 34.5% in the 1st quarter. Deep Keep track of Funds LP now owns 2,599,098 shares of the company’s stock valued at $10,162,000 following purchasing an added 666,058 shares in the last quarter. Fiduciary Team LLC acquired a new stake in shares of Acumen Prescribed drugs in the 1st quarter valued at $31,000. At last, New York Condition Popular Retirement Fund boosted its stake in shares of Acumen Prescription drugs by 337.5% in the 1st quarter. New York Point out Typical Retirement Fund now owns 23,981 shares of the company’s stock valued at $94,000 after buying an extra 18,500 shares in the previous quarter. Institutional buyers and hedge resources very own 64.42% of the company’s stock.
Acumen Prescribed drugs Price tag Overall performance
NASDAQ:ABOS opened at $6.29 on Friday. Acumen Pharmaceuticals has a 12 month minimal of $3.02 and a 12 month significant of $20.29. The company’s 50 working day shifting regular is $4.06 and its 200-day moving average is $4.70.
Acumen Prescription drugs (NASDAQ:ABOS – Get Score) previous unveiled its quarterly earnings effects on Monday, May possibly 16th. The organization described ($.23) EPS for the quarter. Sell-facet analysts forecast that Acumen Pharmaceuticals will put up -.97 EPS for the present calendar year.
About Acumen Prescribed drugs
Acumen Prescribed drugs, Inc, a medical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer’s disorder. The firm focuses on advancing a qualified immunotherapy drug prospect ACU193, a humanized monoclonal antibody that is in Phase I scientific-phase to focus on soluble amyloid-beta oligomers.
Acquire Information & Ratings for Acumen Prescription drugs Everyday – Enter your email tackle down below to receive a concise everyday summary of the most up-to-date news and analysts’ scores for Acumen Pharmaceuticals and associated corporations with MarketBeat.com’s Absolutely free every day e mail newsletter.